Gotowe bibliografie tematyczne / Cancer treatment

Gotowa bibliografia na temat „Cancer treatment”

Autor: Grafiati
Data publikacji: 4 czerwca 2021
Data aktualizacji: 29 lipca 2024

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Spis treści

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Cancer treatment”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Cancer treatment"

1

Shukla, Dr Rajesh, i Dr Sanjay Shukla. "Radiosurgery an Emerging Treatment Option in Cancer Treatment and Non Cancer Condition". Indian Journal of Applied Research 3, nr 12 (1.10.2011): 407–9. http://dx.doi.org/10.15373/2249555x/dec2013/124.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

A, Santhiya Grace, Devi Kala Rathinam D i Sherin J. "Nanorobots in Cancer Treatment". International Journal of Trend in Scientific Research and Development Volume-2, Issue-5 (31.08.2018): 117–20. http://dx.doi.org/10.31142/ijtsrd15782.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Shahab, Ariba, i Subuhi Anwar. "CRUCUMIN ROLE IN BREAST CANCER TREATMENT". Era's Journal of Medical Research 10, nr 01 (czerwiec 2023): 97–103. http://dx.doi.org/10.24041/ejmr2023.16.

Pełny tekst źródła
Streszczenie:
One of the most common forms of malignant tumors is breast cancer worldwide, has a high fatality rate. The development of novel chemicals and technological advancements that will allow the adoption of safer and more efficient therapeutic techniques has received a lot of attention in order to address this problem. In order to maximize tumor growth inhibition and reduce side effects, it has been suggested that combining nanoparticles with well-known anticancer agents including compounds derived from plants, like curcumin is an effective strategy. Curcumin exploits a complex network of molecular signals, including the proliferative, ER, and HER2 pathways, to exert its anticancer actions. According to experimental results, curcumin controls genes associated to cell phase, microRNA, and apoptosis in breast cancer cells.
Style APA, Harvard, Vancouver, ISO itp.
4

Souchelnytskyi, S. "INDIVIDUALIZATION OF CANCER TREATMENT: CONTRIBUTION OF OMICS TECHNOLOGIES TO CANCER DIAGNOSTIC". Biotechnologia Acta 6, nr 4 (2013): 105–17. http://dx.doi.org/10.15407/biotech6.04.105.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

ML, Choudhary. "A Review on Cancer, Cause of Cancer and Treatment: Role of PIK3 Pathway on Cancer". Bioequivalence & Bioavailability International Journal 7, nr 2 (4.07.2023): 1–17. http://dx.doi.org/10.23880/beba-16000208.

Pełny tekst źródła
Streszczenie:
The central function of phosphoinositide 3- kinase (PI3K) activation in tumour cell biology has urged a sizeable trouble to target PI3K and/ or downstream kinases similar as AKT and mammalian target of rapamycin (mTOR) in cancer. still, arising clinical data show limited single- agent exertion of impediments targeting PI3K, AKT or mTOR at permitted boluses. One exception is the response to PI3Kδ impediments in habitual lymphocytic leukaemia, where a combination of cell- natural and- foreign conditioning drive efficacity. Then, we review crucial challenges and openings for the clinical development of impediments targeting the PI3K – AKT – mTOR pathway. Through a lesser focus on patient selection, increased understanding of vulnerable modulation and strategic operation of rational combinations, it should be possible to realize the eventuality of this promising class of targeted anticancer agents.
Style APA, Harvard, Vancouver, ISO itp.
6

Vsevolod, Dolhyi, Avierin Dmytro i Hojouj Mohammad. "Tubulin Role in Cancer Development and Treatment". Cancer Medicine Journal 2, nr 2 (31.12.2019): 45–54. http://dx.doi.org/10.46619/cmj.2019.2-1013.

Pełny tekst źródła
Streszczenie:
This review work is done to show a significance of tubulin in cancer development. Within last decades there are a lot of studies have performed in this area. Now it is clear that there are an enormous number of functions in cell performing by microtubules, a structure unit of which is tubulin. Now it used widely as a predictive factor of tumor aggressiveness, but increasingly it becomes a target for studying and treatment elaboration, since it is well-known that to now a day's tubulin-targeted medicines, such as taxanes or vinca-alkaloids, resistance develops rather quickly, so it consists a large problem in oncology. This work reveals basic microtubule functions, violations that it may undergo and consequences of these. Also it is described here the main modern tendencies in creation of remedy which will make it possible breakthrough treatment resistance barrier.
Style APA, Harvard, Vancouver, ISO itp.
7

Ndukwe, Munachiso Onyedikachi, Ivan Práznovec, Martin Štěpán, Igor Sirák, Aleš Fibír i Jiří Špaček. "Treatment options for locally recurrent vulvar cancer". Česká gynekologie 86, nr 4 (30.08.2021): 246–48. http://dx.doi.org/10.48095/cccg2021246.

Pełny tekst źródła
Streszczenie:
Summary: Objective: Summarizing of treatment options for locally recurrent vulvar cancer in patients after previous complex oncological treatment and presenting a case report from our department. Methods: Presenting a case report of a patient after previous complex oncological treatment for spinocellular cancer of the vulva who presented with a locally recurrent tumor. The patient was treated with a wide radical local excision of the tumor followed by a posterior thigh fl ap graft. Conclusion: Surgical intervention is the primary mode of treatment in locally recurrent cancers of the vulva. Wide radical local excision as a mode of treatment can be optimized by the use of grafts aiding in wound healing.
Style APA, Harvard, Vancouver, ISO itp.
8

Greschuchna, D. "Surgical Treatment of Small Cell Lung Cancer". Journal of the Japanese Association for Chest Surgery 3, nr 2 (1989): 169. http://dx.doi.org/10.2995/jacsurg1987.3.2_169.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

OPRISAN, Emilia, i Mirela ZIVARI. "Psychological Implications of Cancer Treatment in Pregnancy". Revista Romaneasca pentru Educatie Multidimensionala 06, nr 02 (30.12.2014): 29–38. http://dx.doi.org/10.18662/rrem/2014.0602.03.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Tyagi, Nidhi, Ganesh N. Sharma, Birendra Shrivastava, Prasoon Saxena i Nitin Kumar. "Medicinal plants: used in Anti-cancer treatment". International Journal of Research and Development in Pharmacy & Life Sciences 6, nr 5 (sierpień 2017): 2732–39. http://dx.doi.org/10.21276/ijrdpl.2278-0238.2017.6(5).2732-2739.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Rozprawy doktorskie na temat "Cancer treatment"

1

Tong, Ka-keung. "Cancer Treatment Centre". Click to view the E-thesis via HKUTO, 1996. http://sunzi.lib.hku.hk/hkuto/record/B31983066.

Pełny tekst źródła
Streszczenie:
Thesis (M.Arch.)--University of Hong Kong, 1996.
Includes special report study entitled : Hospital planning study for the cancer treatment centre. Includes bibliographical references. Also available in print.
Style APA, Harvard, Vancouver, ISO itp.
2

Tong, Ka-keung, i 唐家強. "Cancer Treatment Centre". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 1996. http://hub.hku.hk/bib/B31983066.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Cha, Kyungduck. "Cancer treatment optimization". Diss., Atlanta, Ga. : Georgia Institute of Technology, 2008. http://hdl.handle.net/1853/22604.

Pełny tekst źródła
Streszczenie:
Thesis (Ph. D.)--Industrial and Systems Engineering, Georgia Institute of Technology, 2008.
Committee Chair: Lee, Eva K.; Committee Member: Barnes, Earl; Committee Member: Hertel, Nolan E.; Committee Member: Johnson, Ellis; Committee Member: Monteiro, Renato D.C.
Style APA, Harvard, Vancouver, ISO itp.
4

Горобченко, Неля Георгіївна, Неля Георгиевна Горобченко, Nelia Heorhiivna Horobchenko i T. Loboda. "Progress in cancer treatment". Thesis, Вид-во СумДУ, 2009. http://essuir.sumdu.edu.ua/handle/123456789/16753.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Горобченко, Неля Георгіївна, Неля Георгиевна Горобченко, Nelia Heorhiivna Horobchenko i T. Loboda. "Progress in cancer treatment". Thesis, Видавництво СумДУ, 2009. http://essuir.sumdu.edu.ua/handle/123456789/7209.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Reuille, Kristina M. "Cancer Treatment-Related Fatigue: Psychometric Testing of the Cancer Treatment-Related Fatigue Representation Scale (CTRFRep) in Patients Undergoing Radiation Treatment for Cancer". Thesis, Connect to resource online, 2009. http://hdl.handle.net/1805/2069.

Pełny tekst źródła
Streszczenie:
Thesis (Ph.D.)--Indiana University, 2009.
Title from screen (viewed on February 2, 2010). School of Nursing, Indiana University-Purdue University Indianapolis (IUPUI). Advisor(s): Janet L. Welch, Juanita F. Keck, Janet S. Fulton, Barbara Manz Friesth. Includes vitae. Includes bibliographical references (leaves 150-164).
Style APA, Harvard, Vancouver, ISO itp.
7

Aubert-Jürgens, Ana. "STAT3 inhibitors for cancer treatment". [S.l.] : [s.n.], 2005. http://elib.tu-darmstadt.de/diss/000563.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Johansson, David. "Bacterial toxins for cancer treatment". Doctoral thesis, Umeå universitet, Medicinsk biovetenskap, 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1637.

Pełny tekst źródła
Streszczenie:
Even though anti‐cancer chemotherapy has been continuously improved during the last decades. problems with adverse effects and drug resistance still constitutes a considerable obstacle and sets a demand for new effective treatment options. Tissue homeostasis in multi‐cellular organisms is maintained through intrinsic cell death, apoptosis, which removes unwanted or damaged cells. Disrupted apoptosis is an important factor in tumorgenesis and drug resistance, therefore induction or restoration of apoptotic pathways is also important for the treatment of cancer. Several naturally occurring bacterial toxins have the ability to induce apoptosis and could thus be candidates to complement or improve the therapeutic effect of other anticancer drugs. The bacterial toxins, adenylate cyclase (AC) toxin from Bordetella pertussis, α‐toxin from Staphylococcus aureus and verotoxin‐1 (VT‐1) from Escherichia coli were investigated for their ability to induce apoptosis in different tumor cell lines. Toxin induction of cell death was investigated by cell viability assays, end‐stage apoptosis induction by DNA‐fregmentation (TUNEL) assay. Toxin receptor expression and signal transduction pathways to apoptosis were investigated by flow cytometry, caspase enzyme activity assays and western blot. Immunohistochemistry was used for identification of toxin receptor expression in tumor tissue samples. AC‐toxin was cytotoxic and induced apoptosis in cultured malignant plural mesothelioma (MPM) and small‐cell lung cancer (SCLC) cells. Low‐toxic concentrations of AC‐toxin enhanced cisplatin cytotoxicity and apoptosis in both cell lines. MPM‐cells with acquired cisplatin resistance were more sensitive to α‐toxin than the less resistant parental MPM cell line. A low‐toxic concentration of α‐toxin re‐sensitized resistant MPM cells to cisplatin cytotoxicity by apoptosis induced through the mitochondrial pathway without detectable activation of common up‐stream apoptosis signalling proteins. VT‐1 was highly cytotoxic and induced apoptosis in globotriosylceramide (Gb3) ‐expressing glioma, breast cancer and non‐small‐cell lung cancer (NSCLC) cells but was not cytotoxic to non‐Gb3‐expressing cells. PPMP, an inhibitor of glucosylceramide synthesis which makes exposed cells unable to synthesize Gb3 rendered Gb3‐expressing cells resistant to VT‐1. MPM cells with acquired‐cisplatin resistance expressed Gb3 in contrast to the absent of expression in the less resistant parental cell line. Gb3, could however be up‐regulated by cisplatin in Gb3‐negative MPM‐cells. Presence of a low‐toxic concentration of VT‐1 potentiated cisplatin‐induced cytotoxicity and apoptosis in the cisplatin‐resistance MPM cell line. VT‐1 was a potent inducer of apoptosis, probably via stress‐induced Mitogen‐activated protein kinase (MAPK)‐signaling involving c‐Jun N‐terminal kinase (JNK) and p38, leading to disruption of the mitochondrial membrane integrety, activation of caspase‐9 and ‐3, and ultimately DNA fragmentation and cell death. Gb3 expression was demonstrated in clinical specimens of glioblastoma and breast cancer making these tumor types interesting for further VT‐1 studies. We conclude that bacterial toxins may be used to induce apoptosis in several types of cancer cells. Low concentrations of verotoxin‐1 and α‐toxin may potentially be used to overcome acquired cisplatin‐resistance in cancer patients.
Style APA, Harvard, Vancouver, ISO itp.
9

Basran, Parminder S. "Optimisation of lung cancer treatment". Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp04/mq22568.pdf.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Wirth, Manfred P., i Oliver W. Hakenberg. "Curative Treatment of Prostate Cancer". Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-133890.

Pełny tekst źródła
Streszczenie:
The guidelines for the curative treatment of prostate cancer presented by the German Society of Urology are discussed. They are based on the current knowledge of the outcomes of surgical and radiotherapeutic treatment for prostate cancer. Radical prostatectomy is recommended as the first-line treatment for organ-confined prostate cancer in patients with an individual life expectancy of at least 10 years. Radiotherapy can be considered as an alternative treatment modality, although current knowledge does not allow a definite assessment of the relative value of radiotherapy compared to radical prostatectomy. Locally advanced cT3 prostate cancer is overstaged in about 20% and curative treatment is possible in selected cases. Guidelines represent rules based on the available evidence. This implies that exceptions must be made whenever appropriate and that guidelines have to be reviewed regularly as new information becomes available
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Książki na temat "Cancer treatment"

1

1939-, Haskell Charles M., i Berek Jonathan S, red. Cancer treatment. Wyd. 4. Philadelphia: W.B. Saunders, 1995.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

1939-, Haskell Charles M., i Berek Jonathan S, red. Cancer treatment. Wyd. 3. Philadelphia: Saunders, 1990.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

1939-, Haskell Charles M., red. Cancer treatment. Wyd. 2. Philadelphia, PA: Saunders, 1985.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Büchler, Markus W., Jürgen Weitz, Bernward Ulrich i Richard John Heald, red. Rectal Cancer Treatment. Berlin, Heidelberg: Springer Berlin Heidelberg, 2005. http://dx.doi.org/10.1007/b139090.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

1955-, Büchler Markus, red. Rectal cancer treatment. Berlin: Springer, 2005.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Price, Pat. Treatment of cancer. Wyd. 4. London: Arnold, 2002.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

West, Brandon S., i Donna R. Stanley. Lung cancer treatment. New York: Nova Science Publishers, 2011.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Karol, Sikora, i Halnan Keith E, red. Treatment of cancer. Wyd. 3. London: Chapman and Hall Medical, 1995.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Banzet, P., J. F. Holland, D. Khayat i M. Weil, red. Cancer Treatment An Update. Paris: Springer Paris, 1994. http://dx.doi.org/10.1007/978-2-8178-0765-2.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Koul, Bhupendra. Herbs for Cancer Treatment. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-32-9147-8.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Części książek na temat "Cancer treatment"

1

Hardcastle, Jack Donald. "Treatment". W Colorectal Cancer, 17–25. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-78225-1_7.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Chun, Hoon Jai, Seun Ja Park, Yun Jeong Lim i Si Young Song. "Treatment". W Gastrointestinal Cancer, 351–57. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-99-0815-8_51.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Lin, Jenny J. "Cancer Treatment". W Caring for Patients Across the Cancer Care Continuum, 93–123. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-01896-2_5.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Al-Mamari, Said Abdallah, i Salim Said Al-Busaidy. "Treatment". W Urological Cancer Management, 257–63. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-16301-7_27.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Al-Mamari, Said Abdallah, i Salim Said Al-Busaidy. "Treatment". W Urological Cancer Management, 81–98. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-16301-7_7.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Gotoda, Takuji. "Endoscopic Treatment". W Gastric Cancer, 149–60. Singapore: Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-13-1120-8_10.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

López, Miguel Alejandro. "Topical Treatment". W Skin Cancer, 301–14. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-7357-2_20.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Chun, Hoon Jai, Seun Ja Park, Yun Jeong Lim i Si Young Song. "Endoscopic Treatment". W Gastrointestinal Cancer, 35–41. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-99-0815-8_6.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Chun, Hoon Jai, Seun Ja Park, Yun Jeong Lim i Si Young Song. "Surgical Treatment". W Gastrointestinal Cancer, 43–50. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-99-0815-8_7.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Chun, Hoon Jai, Seun Ja Park, Yun Jeong Lim i Si Young Song. "Endoscopic Treatment". W Gastrointestinal Cancer, 105–11. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-99-0815-8_15.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Cancer treatment"

1

Antonini, Marcelo, Gabriel Duque Pannain, Steffi Ferreira Buttenbender, Andre Mattar, Odair Ferraro, Maria Clara Alves de Lima Brito, Rodrigo Ferreira Rodrigue i Reginaldo Guedes Coelho Lopes. "Epidemiology of male breast cancer in Brazil: An analysis of patients undergoing treatment in the public health system". W Brazilian Breast Cancer Symposium 2023. Mastology, 2023. http://dx.doi.org/10.29289/259453942023v33s1073.

Pełny tekst źródła
Streszczenie:
Objective: The objective of this study was to understand the epidemiological profile of breast cancer in men in Brazil, in order to improve care for these patients. Methodology: This study is an ecological, observational, cross-sectional analysis based on retrospective data from the publicly available National Oncology Database (DATASUS — SISCAN/Cancer Information System). The study utilized a National Tracking Database as the primary data source. Descriptive analyses of sociodemographic characteristics of patients, including the geographic region of diagnosis, and age range of affected men, were performed. The study also evaluated specific data regarding breast cancer, including clinical staging and types of treatment. The relationship between age group, staging, and treatment according to staging was also evaluated. Results: During the analyzed period of 2017–2021, a total of 4,327 cases of breast cancer in men were diagnosed and recorded in the system, representing 1.81% of all breast cancers registered during this period. The majority of cases were diagnosed in the Southeast region (41%), followed by the Northeast region (37%). In terms of age, the majority of patients were over 54 years (68.9%), with 19.1% of patients between 40 and 54 years, and 12% of all registered cases occurred in patients under 40 years. Clinical examination was used to diagnose 62.8% of men, while imaging examinations were used to diagnose 37.2%. Treatment options included chemotherapy (55.7%), surgical treatment (35.6%), and radiotherapy (8.7%). Conclusion: Breast cancer in men is a rare disease that should not be neglected. It is often diagnosed at more advanced stages, which leads to more invasive treatments. Men with known risk factors should be advised to seek medical attention as soon as they feel a palpable retroareolar mass to ensure a prompt and accurate diagnosis. It is important to raise awareness of this disease and encourage early detection and treatment to improve outcomes for men with breast cancer.
Style APA, Harvard, Vancouver, ISO itp.
2

Venkatesan, Mithra, i Bhuvaneshwari Jolad. "Nanorobots in cancer treatment". W 2010 International Conference on Emerging Trends in Robotics and Communication Technologies (INTERACT 2010). IEEE, 2010. http://dx.doi.org/10.1109/interact.2010.5706154.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Mironidou-Tzouveleki, Maria, Konstantinos Imprialos i Athanasios Kintsakis. "Nanotechnology in cancer treatment". W SPIE NanoScience + Engineering, redaktorzy Hooman Mohseni, Massoud H. Agahi i Manijeh Razeghi. SPIE, 2011. http://dx.doi.org/10.1117/12.898643.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Baltasar Marchueta, Maider. "Cancer treatment and nanotechnology". W MOL2NET'22, Conference on Molecular, Biomedical & Computational Sciences and Engineering, 8th ed. - MOL2NET: FROM MOLECULES TO NETWORKS. Basel, Switzerland: MDPI, 2022. http://dx.doi.org/10.3390/mol2net-08-12470.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Andrade, Gustavo Moreira. "Triple-negative breast cancer: A history of evolution in treatment and prognosis and women’s quality of life". W Brazilian Breast Cancer Symposium 2023. Mastology, 2023. http://dx.doi.org/10.29289/259453942023v33s1057.

Pełny tekst źródła
Streszczenie:
Objective: This study aimed to show the progress in the treatment of triple-negative breast cancer and the impact on the prognosis and quality of life of women. Methodology: A systematic literature review was carried out from the PubMed database, with the descriptors “Breast cancer triple-negative,” “Treatment,” and “Quality of life” with the Boolean operator “AND,” and the filters: “full text,” with a publication date of 2012, 2013, 2022, and 2023, only in women, in the English language. A total of 29 articles were found. Results: In 2012–2013, the treatment for triple-negative cancer was based on the combination of monoclonal antibodies (bevacizumab) with chemotherapy (eribulin), both for tumors in early stages and for metastases, or a radical mastectomy. Both treatments were extremely aggressive for women, with direct consequences on their physical and mental health, as these treatments meant the loss of an organ that symbolizes femininity and the patient’s self-perception as a woman, in addition to excessive hair loss, dryness mucous membranes and skin, changes in appetite, and severe asthenia. In the years 2022–2023, in addition to the therapeutic strategies used 10 years earlier, there was the discovery and advancement in immunotherapy (pembrolizumab), a treatment aimed at activating the immune system against installed cancer. However, the current treatment is about 20 times more expensive than the old one. Conclusion: It was evident that there were small changes in the treatment of triple-negative breast cancer, as there was only the discovery and implementation of immunotherapy, but this small advance allowed a great improvement in the quality of life of patients during treatment. However, this advance is, currently, for a small group of patients, as the world reality is that most patients are unable to pay for immunotherapy and continue with the outdated and archaic therapeutic plan of 10 years ago, continuing with the same complications and heavy consequences on their physical and menthal health.
Style APA, Harvard, Vancouver, ISO itp.
6

Costa, Christina Souto Cavalcante, Rosemar Macedo Sousa Rahal, Leonardo Ribeiro Soares, Gustavo Nader Marta, Debora Sara de Almeida Cardoso i Rafaela Dutra Silva. "OBSTACLES FACED BY BREAST CANCER PATIENTS: FROM EARLY DIAGNOSIS TO TREATMENT DIAGNOSIS TO TREATMENT". W Brazilian Breast Cancer Symposium 2022. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s2039.

Pełny tekst źródła
Streszczenie:
Objective: The objective of this study was to evaluate the factors that influence the early detection and initiation of treatment of patients with breast cancer Methods: This is a cross-sectional, descriptive study, conducted between January and December 2020. A structured study was carried out with 102 patients from a tertiary service in the central region of Brazil. Results: There was a prevalence of women aged 41–60 years (66%), of brown ethnicity (56.9%), and who had completed elementary school (52.9%). In total, 58.8% of women sought the health service annually and 50.0% had never realized mammography (MMG) before the initial symptom, being “nodule” the most cited finding (80.4%). Among the difficulties faced in making the first appointment, fear of the diagnosis was the most cited (83.3%). MMG and biopsy were performed in 56.9% and less than 4 weeks in 56.9% of cases, respectively. In contrast, returns with the result of mammography and biopsy were 67.6% and 71.6%, respectively. In 77.5% of the cases, the specialist consultation after the biopsy occurred within less than 4 weeks and the beginning of treatment in 53.9% of the samples. As for the tumor characteristics, 61.8% of the patients had a positive axilla, 48.0% had tumor stage (G2), and 21.6% with IIIB staging. We observed a predominance of Luminal HER tumors (33.3%) and a mean Ki-67 of 33.46% (±21.22), with 8.8% of metastatic patients at diagnosis. Conclusion: In this sample of women users of the public health service, low awareness and low MMG coverage were observed, culminating in a higher prevalence of advanced stages at diagnosis. Confronting the obstacles related to the diagnosis and treatment of breast cancer can attenuate the socioeconomic differences and improve the oncological outcomes in this population.
Style APA, Harvard, Vancouver, ISO itp.
7

Son, Joo-Hiuk. "Active Demethylation of Cancer Cells using Terahertz Radiation for Potential Cancer Treatment". W Conference on Lasers and Electro-Optics/Pacific Rim. Washington, D.C.: Optica Publishing Group, 2022. http://dx.doi.org/10.1364/cleopr.2022.cmp3a_02.

Pełny tekst źródła
Streszczenie:
Carcinogenesis involves DNA methylation which is a primary alteration in DNA in the development of cancer before genetic mutation. Because the abnormal DNA methylation is found in most cancer cells, the assessment of DNA methylation using terahertz radiation can be a novel optical method to detect and control cancer. The methylation has been directly observed by terahertz time-domain spectroscopy and this epigenetic chemical change could be manipulated to the state of demethylation using resonant terahertz radiation. Demethylation of cancer cells is a key issue in epigenetic cancer therapy and our results may lead to the treatment of cancer using electromagnetic waves.
Style APA, Harvard, Vancouver, ISO itp.
8

da Silva, Ana Paula, Marcelo Saito Nogueira, Javier Jo, Vanderlei S. Bagnato i Natalia M. Inada. "Optical Based Diagnosis and Treatment of Onychomycosis". W Cancer Imaging and Therapy. Washington, D.C.: OSA, 2016. http://dx.doi.org/10.1364/cancer.2016.jtu3a.37.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Sivasankaran, Nivetha. "Biosensor and breast cancer treatment". W 2015 International Conference on Robotics, Automation, Control and Embedded Systems (RACE). IEEE, 2015. http://dx.doi.org/10.1109/race.2015.7097239.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Chen, Wei R. "laser immunotherapy for cancer treatment". W Asia Communications and Photonics Conference. Washington, D.C.: OSA, 2013. http://dx.doi.org/10.1364/acp.2013.ath3l.3.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Raporty organizacyjne na temat "Cancer treatment"

1

Ramsey, Imogen, Kate Kennedy, Deborah Forsythe, Micah Peters, Greg Sharplin, Nadia Corsini i Marion Eckert. Cancer control plans. The Sax Institute, czerwiec 2020. http://dx.doi.org/10.57022/jkea9139.

Pełny tekst źródła
Streszczenie:
This review, commissioned by the NSW Cancer Institute, highlights key trends and common elements of cancer control plans from Australia and countries with health systems similar to NSW. It will be used as the basis for a discussion paper in the development of the next NSW Cancer Plan. A clear message from the review is the need for plans to be tailored to the local context, to consider the most prevalent cancers and at risk populations, to respond to the needs of stakeholders, to have detailed actionable outcomes, to be appropriately resourced and to have a clear plan for implementation and evaluation. Common elements of included plans were: prevention, screening and early detection, treatment, survivorship and palliative care, coordination between services, approaches to specific populations, research and training, workforce, implementation, evaluation and monitoring, and trends for cancer control
Style APA, Harvard, Vancouver, ISO itp.
2

Ackermann, A. L., i R. V. Dorn, III. PBF/BNCT Program for cancer treatment. Office of Scientific and Technical Information (OSTI), październik 1989. http://dx.doi.org/10.2172/7018380.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Ackermann, A. L., i R. V. Dorn, III. PBF/BNCT Program for cancer treatment. Office of Scientific and Technical Information (OSTI), wrzesień 1989. http://dx.doi.org/10.2172/7018387.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Ackermann, A. L., i R. V. Dorn, III. PBF/BNCT Program for cancer treatment. Office of Scientific and Technical Information (OSTI), sierpień 1989. http://dx.doi.org/10.2172/7018390.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Ackermann, A. L., i R. V. Dorn, III. PBF/BNCT Program for cancer treatment. Office of Scientific and Technical Information (OSTI), listopad 1989. http://dx.doi.org/10.2172/7067837.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Parsons, Helen M. Nutrition as Prevention for Improved Cancer Health Outcomes. Agency for Healthcare Research and Quality (AHRQ), maj 2023. http://dx.doi.org/10.23970/ahrqepccer260.

Pełny tekst źródła
Streszczenie:
Objective. To understand the evidence base for nutrition interventions delivered prior to or during cancer treatment for preventing and treating negative cancer and cancer treatment–related outcomes among individuals with or at risk for malnutrition. The primary purpose was to inform the National Institutes of Health (NIH) Pathways to Prevention workshop Nutrition as Prevention for Improved Cancer Health Outcomes, held July 26–28, 2022. Data sources. We searched Ovid Medline, Ovid Embase, and Cochrane Central Register of Controlled Trials to identify studies from 2000 through July 2022. We conducted grey literature searches to identify additional resources relevant to the associated costs or value (e.g., cost-effectiveness, cost-benefit) of nutrition interventions. Review methods. The review was guided by a set of Key Questions established by the NIH planning committee for the Nutrition as Prevention for Improved Cancer Health Outcomes workshop. We searched for studies that evaluated a broad range of nutrition interventions (e.g., dietary supplements, nutrition support, nutrition counseling) for preventing and treating negative outcomes of cancer and cancer-related treatment. Eligible studies included randomized controlled trials (RCTs) with enrollment ≥50 participants. We extracted basic study information from all eligible studies, then grouped studies by broad intervention and cancer types. We provide a detailed evidence map for all included studies, but conducted risk of bias and additional qualitative descriptions of outcomes for only those intervention and cancer types with a larger volume of literature. Results. We identified 9,798 unique references, with 206 studies from 219 publications reporting RCTs of nutrition interventions to potentially improve negative outcomes of cancer and cancer-related treatment. Two decades of randomized trial evidence on nutrition interventions for adults prior to and/or during cancer treatment primarily focused on dietary supplements, nutrition support (including oral nutrition supplements), and the route or timing of nutrition interventions for gastrointestinal and head and neck cancers in the inpatient setting. Most studies evaluated changes in body weight/composition, adverse events, length of hospital stay, and quality of life. Few studies were conducted within the U.S. setting. Among intervention and cancer types with a high volume of literature (n=114), which predominantly included studies in dietary supplements and nutrition support in gastrointestinal and head and neck cancers, 11 percent (n=12) were rated as low risk of bias (higher quality), 40 percent (n=46) medium risk of bias, and 49 percent (n=56) high risk of bias (lower quality). Low and medium risk-of-bias studies reported mixed results on the effect of nutrition interventions across cancer and treatment-related outcomes. Although the evidence map shows a large volume of studies evaluating nutrition interventions and outcomes, these studies showed high heterogeneity across study populations, interventions, and outcomes (measure definitions, timing of measurements), even within nutrition intervention categories; as a result, we could not aggregate results. While studies enrolled individuals from multiple cancer types, treatments, and stages, across the lifespan, with varying degrees of muscle wasting, and in those with a range of comorbid conditions, no eligible studies specifically evaluated whether the effects of nutrition interventions on preventing negative outcomes varied across these characteristics. Among studies included in our Key Questions, we found that few (4%, n=8) published cost or value (e.g., cost-effectiveness, cost-benefit) information related to the intervention. In our grey literature search of additional studies examining cost or value of nutrition interventions, we found few studies that conducted cost-effectiveness or cost-benefit analyses; among those that did, we found the studies were conducted in non-U.S. health systems and demonstrated mixed results on the value of nutrition interventions. Conclusions. Although overall RCT evidence focused on a wide range of nutrition interventions, studies were concentrated in use of dietary supplements, nutrition support, and the route or timing of nutrition interventions within gastrointestinal and head and neck cancers in inpatient settings. Among interventions with the highest volume of literature, the majority of studies were rated as high risk of bias. Our findings point to the need for rigorous new research to bolster the evidence base. Specifically, the field needs a more detailed future evaluation of a subset of nutrition interventions contained in this evidence map that focuses on priorities most relevant to specific stakeholders (e.g., oncologists, patients, dietitians, researchers, policymakers). Further, studies should be specifically designed to evaluate the main outcomes of interest for clinical practice. Future research would also benefit from creation of standardized taxonomies for interventions and outcomes as well as more rigorous design and reporting of nutrition interventions. As mentioned, heterogeneity of populations, interventions, comparators, and outcomes precluded aggregation. Currently, the quality and heterogeneity of the studies limit translation of findings into clinical practice or guidelines. In order to inform development of these guidelines, coordinated efforts are required to develop detailed conceptual frameworks for mechanisms of nutrition interventions most relevant to clinical care providers and patients. Such frameworks would help inform priorities for future research as well as guide practice and policy.
Style APA, Harvard, Vancouver, ISO itp.
7

Boyes, Allison, Jamie Bryant, Alix Hall i Elise Mansfield. Barriers and enablers for older people at risk of and/or living with cancer to accessing timely cancer screening, diagnosis and treatment. The Sax Institute, lipiec 2022. http://dx.doi.org/10.57022/ieoy3254.

Pełny tekst źródła
Streszczenie:
• Older adults have complex and unique needs that can influence how and when cancer is diagnosed, the types of treatment that are offered, how well treatment is tolerated and treatment outcomes. • This Evidence Check review identified 41 studies that specifically addressed barriers and enablers to cancer screening, diagnosis and treatment among adults aged 65 years and older. • Question 1: The main barriers for older people at risk of and/or living with cancer to access and participate in timely cancer screening relate to lack of knowledge, fear of cancer, negative beliefs about the consequences of cancer, and hygiene concerns in completing testing. The main enablers to participation in timely cancer screening include positive/helpful beliefs about screening, social influences that encourage participation and knowledge. • Question 2: The main barriers for older people at risk of and/or living with cancer to access and/or seek timely cancer diagnosis relate to lack of knowledge of the signs and symptoms of cancer that are distinct from existing conditions and ageing, healthcare accessibility difficulties, perceived inadequate clinical response from healthcare providers, and harmful patient beliefs about risk factors and signs of cancer. The main enablers to accessing and/or seeking a timely cancer diagnosis include knowledge of the signs and symptoms of cancer, and support from family and friends that encourage help-seeking for symptoms. • Question 3: The main barriers for older people at risk of and/or living with cancer in accessing and completing cancer treatment include discrimination against patients in the form of ageism, lack of knowledge, patient concern about the adverse effects of treatment, predominantly on their independence, healthcare accessibility difficulties including travel and financial burden, and patients’ caring responsibilities. The main enablers to accessing and completing cancer treatment are social support from peers in a similar situation, family and friends, the influence of healthcare providers, and involving patients in treatment decision making. • Implications. The development of strategies to address the inequity of cancer outcomes in people aged 65 years and older in NSW should consider: ­ Increasing community members’ and patients’ knowledge and awareness by providing written information and decision support tools from a trusted source ­ Reducing travel and financial burden by widely disseminating information about existing support schemes and expanding remote patient monitoring and telehealth ­ Improving social support by promoting peer support, and building the support capacity of family carers ­ Addressing ageism by supporting patients in decision making, and disseminating education initiatives about geriatric oncology to healthcare providers ­ Providing interdisciplinary geriatric oncology care by including a geriatrician as part of multidisciplinary teams and/or expanding geriatric oncology clinics.
Style APA, Harvard, Vancouver, ISO itp.
8

Freire, Mariana, Diana Martins, Maria Filomena Botelho i Fernando Mendes. Biomarkers of resistance mechanisms in innovative lung cancer treatments - A systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, wrzesień 2022. http://dx.doi.org/10.37766/inplasy2022.9.0011.

Pełny tekst źródła
Streszczenie:
Review question / Objective: This systematic review aims to provide an overview of the immunotherapy resistance mechanisms and identify potential biomarkers associated with immunotherapy response in NSCLC, as well as examine new treatment options to overcome this hurdle. Condition being studied: Lung Cancer (LC) remains one of the leading cancers worldwide. In 2020, were globally estimated 2 206 771 new cases and 1 796 144 deaths, representing the uttermost frequent cause of cancer death. LC is classified histologically into small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC), being the last one the most common, representing 80 to 85% of all LC. The three predominantly subtypes of NSCLC are lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC) and large cell carcinoma (LCLC). NSCLC is usually diagnosed in advanced-staged disease due to ambiguous and delayed severe symptoms.
Style APA, Harvard, Vancouver, ISO itp.
9

Chen, Ziying, Zefei Jiang, Ziyun Guo, Mengchao Wang, Zhen Wang i Liwei Chen. Comparative efficacy of different types of acupuncture for cancer-related fatigue: a protocol for systematic review and network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, lipiec 2022. http://dx.doi.org/10.37766/inplasy2022.7.0012.

Pełny tekst źródła
Streszczenie:
Review question / Objective: To evaluate the efficacy and safety of all current acupuncture therapies for the treatment of CRF through network meta-analysis. Condition being studied: Cancer-related fatigue (CRF) has been defined as a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer and/or cancer treatment that is not proportional to recent activity and interferes with usual functioning, as one of the most common symptoms in cancer and related therapies, presents a huge challenge to the quality of life for cancer patients. Unlike general fatigue that can be relieved with rest, CRF is more debilitating, more persistent, and manifests itself in various ways, both physically and mentally. The estimated prevalence of CRF varies widely by various fatigue evaluation indicators, types of cancer, and cancer treatments, ranging from 14.03% to 100%, however, the latest systematic review show that it can have a pooled prevalence of up to 52%, this deserves our attention. But there has been no gold standard treatment for CRF.
Style APA, Harvard, Vancouver, ISO itp.
10

Adamson, Eileen D. Cripto: A Target for Breast Cancer Treatment. Fort Belvoir, VA: Defense Technical Information Center, czerwiec 2005. http://dx.doi.org/10.21236/ada438430.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „Cancer treatment” dla poszczególnych typów źródeł:
Artykuły w czasopismach Rozprawy doktorskie Książki
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii